A Multicenter, Single Arm, Open-label Trial of Prasugrel Monotherapy After PCI With the SYNERGY® Stent in Patients With Chronic Coronary Syndrome or Non-ST-elevation Acute Coronary Syndromes
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 307
- 试验地点
- 13
- 主要终点
- Rate of Primary Ischemic Endpoint events (CCS)
研究概览
简要总结
The ASET Japan Pilot study is a multicenter, single arm, open-label trial of single antiplatelet therapy with prasugrel for patients undergoing successful and optimal Percutaneous Coronary Intervention (PCI) for Chronic Coronary Syndrome (CCS) and Non-ST elevation Acute coronary syndrome (NSTE-ACS). The enrollment consists of two phases: i) 200 patients presenting with CCS; ii) 200 patients presenting with NSTE-ACS. The patients will be loaded with standard dual antiplatelet therapy according to local practice (usually aspirin 81 to 330 mg and clopidogrel 300 mg or prasugrel 20 mg or ticagrelor 180 mg, unless patient is on long-term therapy) prior to the PCI procedure. After PCI, if the results are considered to be satisfactory by the operator based on clinical (e.g. clinical status, ECG, etc.), angiographic and/or findings from intracoronary imaging, only then patients will be enrolled in the study and loaded with prasugrel 20 mg if the patients have not loaded prasugrel prior to PCI or have not taken a maintenance dose of prasugrel before the index PCI. Patients continued with prasugrel only (3.75 mg once a day) for three months in CCS patients and for 12 months in NSTE-ACS patients. Aspirin, clopidogrel, and ticagrelor will be discontinued just after the index procedure.
i. CCS patients (phase 1): At the 3-months follow-up visit, prasugrel monotherapy will be replaced by aspirin monotherapy or dual-antiplatelet therapy according to local standard of care. Clinical follow-up with office visit will be performed at 3 months and telephone contacts at 1, and 4 months (final follow-up).
ii. NSTE-ACS patients (phase 2): At the 12-months follow-up visit, prasugrel monotherapy will be replaced by aspirin monotherapy for an observational period of 1 month, followed by antiplatelet treatment according to local practice. Clinical follow-up with office visit will be performed at 1 and 12 months and telephone contacts at 3, 6, 9 and 13 months (final follow-up).
All events will be adjudicated by an independent clinical events committee (CEC).
An independent Data Safety and Monitoring Board (DSMB) will monitor the individual and collective safety of the patients in the study during enrolment of CCS patients and up to 3 months follow-up of CCS patients, and during enrollment of NSTE-ACS patients and up to 12 months follow-up of NSTE-ACS patients (timepoint for primary endpoint).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion Criteria for CCS patients (phase 1) :
- •Successful PCI with optimal acute stent implantation of one or more SYNERGY stent(s).
- •SYNERGY stent implantation was performed to treat:
- •at least one de novo lesion with ≥50% diameter stenosis determined by visual assessment in at least one native coronary artery with a vessel size between 2.25 mm and 5.0 mm in diameter.
- •Non-acute coronary disease, with normal cardiac biomarker values prior to the PCI procedure, and evidences of myocardial ischemia by symptoms or non-invasive/invasive testing.
- •patients with anatomical SYNTAX Score < 23 prior to PCI
- •Patient has provided written informed consent as approved by the Ethical Committee of the respective clinical site.
- •Inclusion Criteria for NSTE-ACS patients (phase 2) :
- •Patients with diagnosed Non ST-elevation acute coronary syndrome
- •Patients with anatomical SYNTAX Score < 23 prior to PCI
- •Patient provided written informed consent as approved by the Ethical Committee of the respective clinical site
- •Post PCI criteria for NSTE-ACS patients
- •Patient is free of angina symptoms at the end of PCI procedure.
- •Successful PCI with optimal acute stent implantation of one or more SYNERGY stent(s).
- •SYNERGY stent implantation was performed to treat at least one de novo lesion with ≥50% diameter stenosis determined by visual assessment in at least one native coronary artery with a vessel size between 2.25 mm and 5.0 mm in diameter.
排除标准
- •Exclusion Criteria for CCS patients (phase 1):
- •Candidates will be ineligible for enrolment in the study if any of the following conditions apply:
- •≤ 20 years of age
- •Unable to give Informed Consent
- •Females of child-bearing potential unless negative pregnancy test at screening and willing to use effective contraception for the duration of treatment with study medication
- •Female who is breastfeeding at time of enrolment
- •Patients concomitantly received any other non-study stent at the same procedure
- •Patients with planned PCI or surgical intervention to treat any cardiac or non-cardiac condition;
- •Previous PCI with any non-SYNERGY stents in the last 6 months
- •Current (same hospitalization) or previous (within 12 months) acute coronary syndrome
- •Patient with following lesion characteristics prior to PCI; Saphenous or arterial graft, in-stent (re)stenosis
- •History of definite stent thrombosis
- •Concomitant cardiac valve disease requiring invasive therapy
- •Atrial fibrillation or other indication for oral anticoagulant therapy
- •Known allergy to aspirin, prasugrel or diagnosed lactose intolerance
- •Acute heart failure
- •Active myocarditis
- •Cardiomyopathy
- •Patient in hemodialysis
- •Treatment in the last 10 days or requirement for ongoing treatment with a strong CYP3A4 inhibitor or inducer;
- •History of stroke or transient ischemic cerebrovascular accident
- •History of intracranial hemorrhage or other intracranial pathology associated with increased bleeding risk
- •Hemoglobin <10 g/dL or other evidence of active bleeding
- •Peptic ulceration documented by endoscopy within the last 3 months unless healing proven by repeat endoscopy
- •Any other condition deemed by the investigator to place the patient at excessive risk of bleeding with prasugrel
- •Participation in another trial with an investigational drug or device
- •Co-morbidity associated with life expectancy <1 year
- •Assessment that the subject is not likely to comply with the study procedures or have complete follow-up
- •Known drug or alcohol dependence within the past 12 months as judged by the investigator
- •Exclusion Criteria for NSTE-ACS patients (Phase 2):
- •Candidates will be ineligible for enrolment if any of the following conditions apply:
- •≤ 20 years of age
- •Unable to give Informed Consent
- •Females of child-bearing potential unless negative pregnancy test at screening and willing to use effective contraception for the duration of treatment with study medication
- •Female who is breastfeeding at time of enrolment
- •Patients concomitantly received any other non-study stent at the same procedure
- •Patients with planned PCI or surgical intervention to treat any cardiac or non-cardiac condition;
- •Previous PCI with any non-SYNERGY stents in the last 6 months
- •Patient with following lesion characteristics prior to PCI; Saphenous or arterial graft, in-stent (re)stenosis
- •History of definite stent thrombosis
- •Concomitant cardiac valve disease requiring invasive therapy
- •Known allergy to aspirin, prasugrel or diagnosed lactose intolerance
- •Atrial fibrillation or other indication for oral anticoagulant therapy;
- •History of stroke or transient ischemic cerebrovascular accident
- •History of intracranial haemorrhage or other intracranial pathology associated with increased bleeding risk
- •Acute heart failure
- •Active myocarditis
- •Cardiomyopathy
- •Patient in hemodialysis
- •Haemoglobin <10 g/dL or other evidence of active bleeding
- 另有 11 项未显示
研究组 & 干预措施
Prasugrel Monotherapy
The patients will be loaded with standard dual antiplatelet therapy according to local practice (usually aspirin 81 to 330 mg and clopidogrel 300 mg or prasugrel 20 mg or ticagrelor 180 mg, unless patient is on long-term therapy) prior to the PCI procedure. After PCI, if the results are considered to be satisfactory by the operator based on clinical (e.g. clinical status, ECG, etc.), angiographic and/or findings from intracoronary imaging, only then patients will be enrolled in the study and loaded with prasugrel 20 mg if the patients have not loaded prasugrel prior to PCI or have not taken a maintenance dose of prasugrel before the index PCI. Patients continued with prasugrel only (3.75 mg once a day) for three months in CCS patients and for 12 months in NSTE-ACS patients. Aspirin, clopidogrel, and ticagrelor will be discontinued just after the index procedure.
干预措施: prasugrel Monotherapy (Drug)
结局指标
主要结局
Rate of Primary Ischemic Endpoint events (CCS)
时间窗: 3 months
Composite of cardiac death, target-vessel myocardial infarction (spontaneous \>48 hours) or definite stent thrombosis.
Rate of Primary Ischemic Endpoint events (NSTE-ACS)
时间窗: 12 months
Composite of cardiac death, target-vessel myocardial infarction (spontaneous \>48 hours) or definite stent thrombosis.
Rate of Primary Bleeding Endpoint event (CCS)
时间窗: 3 months
BARC 3 or 5 bleeding
Rate of Primary Bleeding Endpoint event (NSTE-ACS)
时间窗: 12 months
BARC 3 or 5 bleeding
次要结局
未报告次要终点
研究者
Yoshinobu Onuma
Professor of interventional Cardiology
National University of Ireland, Galway, Ireland